Skip to main content

Table 1 Distribution of matching criteria and other patient characteristics in the cohort of patients receiving 5 × 5 Gy (n = 32) and in those patients receiving 10 × 3 Gy (n = 64)

From: Comparison of 5 × 5 Gy and 10 × 3 Gy for metastatic spinal cord compression using data from three prospective trials

  5 × 5 Gy
N patients
10 × 3 Gy
N patients
P
Type of primary tumor    1.00
 Breast cancer 7 (22%) 14 (22%)  
 Prostate cancer 2 (6%) 4 (6%)  
 Myeloma/lymphoma 3 (9%) 6 (9%)  
 Lung cancer 9 (28%) 18 (28%)  
 Other tumors 11 (34%) 22 (34%)  
Ambulatory prior to radiotherapy    1.00
 Not ambulatory 12 (38%) 24 (38%)  
 Ambulatory 20 (63%) 40 (63%)  
Time developing motor deficits prior to radiotherapy    1.00
 Faster development (1–7 days) 9 (28%) 18 (28%)  
 Slower development (> 7 days) 23 (72%) 46 (72%)  
Interval between tumor diagnosis and MSCC    1.00
 ≤ 12 months 17 (53%) 34 (53%)  
 > 12 months 15 (47%) 39 (47%)  
Visceral metastases at the time of radiotherapy    1.00
 No 11 (34%) 22 (34%)  
 Yes 21 (66%) 42 (66%)  
Median age (range) 63 (36–79) years 65 (38–86) years 0.35
Gender    0.83
 Female 13 (41%) 28 (44%)  
 Male 19 (59%) 36 (56%)  
Eastern Cooperative Oncology Group performance score    0.66
 1–2 15 (47%) 26 (41%)  
 3–4 17 (53%) 38 (59%)  
Number of vertebrae affected by MESCC    0.83
 1–2 20 (63%) 38 (59%)  
  3 12 (38%) 26 (41%)  
Other bone metastases at the time of radiotherapy    1.00
 No 7 (22%) 15 (23%)  
 Yes 25 (78%) 49 (77%)  
  1. The p value for the comparison regarding age was obtained with the Mann-Whiney U test, otherwise p values were obtained with the Fisher’s exact test